Anhedonia is a core feature of major depressive disorder (MDD) that is frequently resistant to available treatments. Psilocybin's specific efficacy for anhedonia remains unclear. To evaluate psilocybin's efficacy for anhedonia in treatment-resistant MDD. In this randomized, double-blind, placebo-controlled trial, 20 participants with treatment-resistant MDD received psilocybin (25 mg or 1 mg)...
Introduction: In Colorado, both cannabis and psilocybin are legal and becoming more commonly used. However, there is almost no research detailing the public health concerns regarding negative outcomes (e.g., dependence) of cannabis and psilocybin co-use and motives that may perpetuate these negative outcomes (e.g., coping, boredom). Methods: Using data from a larger observational study on...